Skip to Main Content
Table 1.

Patient characteristics

All PSMA-PET patients (N = 200)PSADT of ≤10 months (n = 115)Gleason score ≥8 only (n = 85)SPARTAN (N = 1,207)
Age (years) 
 Median (range) 71 (46–94) 71 (46–94) 73 (48–86) 74 (48–97) 
Prostate-specific antigen (ng/mL) 
 Median (range) 5.3 (1.3a–263.8) 5.2 (1.3a–263.8) 5.4 (2.0–99.1) 7.8 (0.1–294.8) 
Prostate-specific antigen doubling time (months) n = 132  n = 17  
 Median (range) 4.0 (0.0–90.0) 3.6 (0.0–10.0) Not applicable 4.4 (0.7–10.0) 
 ≤6 85 (64) 85 (74) Unknown 860 (71) 
 >6 47 (36) 30 (26) 17 (100) 347 (29) 
Gleason score n = 193 n = 108  n = 1171 
 <8 42 (22) 42 (39) 0 (0) 661 (56) 
 ≥8 151 (78) 66 (61) 85 (100) 510 (44) 
Prior therapy     
 Prior prostate cancer–related surgery 130 (65) 79 (69) 51 (60) 682 (57) 
 Prior prostate cancer–related radiotherapy 104 (52) 69 (60) 35 (41) 696 (58) 
All PSMA-PET patients (N = 200)PSADT of ≤10 months (n = 115)Gleason score ≥8 only (n = 85)SPARTAN (N = 1,207)
Age (years) 
 Median (range) 71 (46–94) 71 (46–94) 73 (48–86) 74 (48–97) 
Prostate-specific antigen (ng/mL) 
 Median (range) 5.3 (1.3a–263.8) 5.2 (1.3a–263.8) 5.4 (2.0–99.1) 7.8 (0.1–294.8) 
Prostate-specific antigen doubling time (months) n = 132  n = 17  
 Median (range) 4.0 (0.0–90.0) 3.6 (0.0–10.0) Not applicable 4.4 (0.7–10.0) 
 ≤6 85 (64) 85 (74) Unknown 860 (71) 
 >6 47 (36) 30 (26) 17 (100) 347 (29) 
Gleason score n = 193 n = 108  n = 1171 
 <8 42 (22) 42 (39) 0 (0) 661 (56) 
 ≥8 151 (78) 66 (61) 85 (100) 510 (44) 
Prior therapy     
 Prior prostate cancer–related surgery 130 (65) 79 (69) 51 (60) 682 (57) 
 Prior prostate cancer–related radiotherapy 104 (52) 69 (60) 35 (41) 696 (58) 

NOTE: Data are number of patients (%) unless otherwise indicated.

aTwo eligible patients had prostate-specific antigen ≤2 ng/mL at time of PSMA-PET.

Close Modal

or Create an Account

Close Modal
Close Modal